drugset / Trial / NCT01466595

Rifaximin as a Modulator of Microbial Translocation and Immune Activation

NCT01466595

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is being done to see whether rifaximin, an antibiotic that works in the intestines, can lower the amount of germs in the intestines of HIV infected persons. It is possible that when the amount of these germs is lowered, an HIV-infected person's immune system will become less active and will have a better chance of recovering. Also, the study will evaluate the safety of using rifaximin in HIV-infected subjects.

Timeline

Start
2011-09
Primary completion
2012-09
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifaximin Other / unclassified 550 mg Oral